WeVote
Log In

Bill

Bill

SB 227

AN ACT ESTABLISHING A TASK FORCE TO STUDY OVER-THE-COUNTER DIET PILLS AND SUPPLEMENTS AND PROTECT THE PRIVACY OF PRESCRIBERS OF PRESCRIPTION DRUGS FOR REPRODUCTIVE HEALTH CARE AND GENDER-AFFIRMING HEALTH CARE.

2026 Regular Session Introduced by Julie Kushner and 2 co-sponsors

Connecticut bill establishes labeling, ingredient disclosure, and marketing standards for prescription drugs, diet pills, and dietary supplements to protect consumers from unsafe or misrepresented products.

FILE NO. 216
#advancedpracticenurses #children #consumerprotectiondepartment #dietarysupplements #drugs #employees #fines(penalties) #healthcaredata #infertility #medicalcare #notices #nurses #pharmacycommission #physicianassistants #privacy #reports #retailtrade #sex(gender) #taskforces #violations #weightloss
0
WeVote Research Nonpartisan
Bill Summary · SB 227

Legislative bill overview

SB 227 regulates the sale and marketing of prescription drugs, over-the-counter diet pills, and dietary supplements in Connecticut. The bill establishes standards for product labeling, ingredient disclosure, and potentially restricts certain substances or marketing practices related to these products. It aims to protect consumers from misleading claims and unsafe ingredients in weight-loss and health-related products.

Why is this important

Diet pills and supplements are largely unregulated by the FDA and often make unsubstantiated health claims, potentially exposing consumers to harmful ingredients or ineffective products. Connecticut residents spend hundreds of millions annually on these products, making consumer protection in this market a legitimate public health concern. Clear labeling and ingredient standards can help prevent adverse health events and reduce deceptive marketing practices.

Potential points of contention

  • Industry burden vs. consumer protection: Retailers and manufacturers may argue compliance costs are excessive, while consumer advocates contend stronger regulations are necessary given past harmful product incidents
  • State vs. federal authority: Questions about whether Connecticut should establish standards that differ from federal FDA guidelines, potentially creating market fragmentation
  • Definition scope: Disagreement over what qualifies as a "supplement" versus a "drug," which affects which products face which regulations and could impact access to certain products

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.